Skip to content
Screener

Ultragenyx Pharmaceutical RARE EPS (Basic)

EPS (Basic) at other companies

Eli Lilly logo
Eli LillyLLY
$7.95+26.2%
Amgen logo
AmgenAMGN
$4.40+65.4%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$0.69-188%
Arrowhead Research logo
Arrowhead ResearchARWR
-$0.93-133%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0.14-88.7%
Regenxbio logo
RegenxbioRGNX
$0.43+131%

Other financials

Income statement

See full
Revenue$214.0M+28.1%
Operating income-$75.0M+30.6%
Net income-$92.0M+20.0%
EPS (diluted)-$0.90+23.1%

Balance sheet

See full
Cash & equivalents$125.0M-29.0%
Total debt$36.0M-10.8%
Total equity-$291.0M-293%
Total assets$1.3B-3.2%

Cash flow

See full
Operating cash flow-$97.0M+11.0%
CapEx$1.0M-66.7%
Free cash flow-$98.0M+12.5%

Valuation

See full
Market cap$2.55B-5.8%
P/S3.6×-0.9×

Profitability

See full
Gross margin97.2%—
Operating margin-73.6%-7.3pp
Net margin-81.7%-4.9pp
FCF margin-68.2%-1.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×—
Current ratio1.7×-0.7×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333233
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest income561113
Non-cash interest expense on liabilities for sales of future royalties(22)(14)(43)(28)
Other income1212
Loss before income taxes(91)(114)(275)(264)
Provision for income taxes(1)(1)(2)(2)
Net loss$(92)$(115)$(277)$(266)
Net loss per share, basic and diluted$(0.90)$(1.17)$(2.73)$(2.73)
Shares used in computing net loss per share, basic and diluted101.998.5101.397.4

Item 1. Financial Statements

FAQ

What is Ultragenyx Pharmaceutical's EPS (basic)?
Ultragenyx Pharmaceutical (RARE) reported EPS (basic) of -$0.90 in Q2 2026.
How has Ultragenyx Pharmaceutical's EPS (basic) changed year-over-year?
Ultragenyx Pharmaceutical's EPS (basic) increased by 23.1% year-over-year, from -$1.17 to -$0.90.
What is the long-term trend for Ultragenyx Pharmaceutical's EPS (basic)?
Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's EPS (basic) has grown at a -3.4% compound annual growth rate (CAGR), from -$6.70 to -$5.83.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.

Ask your AI about Ultragenyx Pharmaceutical's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude